WO2009054468A1 - Azolecarboxamide compound or salt thereof - Google Patents

Azolecarboxamide compound or salt thereof Download PDF

Info

Publication number
WO2009054468A1
WO2009054468A1 PCT/JP2008/069263 JP2008069263W WO2009054468A1 WO 2009054468 A1 WO2009054468 A1 WO 2009054468A1 JP 2008069263 W JP2008069263 W JP 2008069263W WO 2009054468 A1 WO2009054468 A1 WO 2009054468A1
Authority
WO
WIPO (PCT)
Prior art keywords
urinary tract
lower urinary
salt
pain
azolecarboxamide
Prior art date
Application number
PCT/JP2008/069263
Other languages
French (fr)
Japanese (ja)
Inventor
Keizo Sugasawa
Kenichi Kawaguchi
Takaho Nomura
Shunichiro Matsumoto
Takashi Shin
Hidenori Azami
Tomoaki Abe
Akira Suga
Ryushi Seo
Masayuki Tanahashi
Toru Watanabe
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK08842145.8T priority Critical patent/DK2206707T3/en
Priority to JP2009538260A priority patent/JP5321467B2/en
Priority to PL08842145T priority patent/PL2206707T3/en
Priority to US12/739,433 priority patent/US8304547B2/en
Priority to KR1020107006536A priority patent/KR101504787B1/en
Priority to CA2703106A priority patent/CA2703106C/en
Priority to CN2008801138204A priority patent/CN101835764B/en
Priority to BRPI0818201A priority patent/BRPI0818201B8/en
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to SI200831299T priority patent/SI2206707T1/en
Priority to ES08842145.8T priority patent/ES2498065T3/en
Priority to MX2010004499A priority patent/MX2010004499A/en
Priority to EP08842145.8A priority patent/EP2206707B1/en
Priority to AU2008314922A priority patent/AU2008314922B2/en
Publication of WO2009054468A1 publication Critical patent/WO2009054468A1/en
Priority to IL205071A priority patent/IL205071A/en
Priority to ZA2010/02608A priority patent/ZA201002608B/en
Priority to HRP20140970AT priority patent/HRP20140970T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

[PROBLEMS] To provide a therapeutic or prophylactic agent for frequent urination, urinary urgency or urinary incontinence associated with a lower urinary tract disease including overactive bladder, a lower urinary tract disease accompanied by a lower urinary tract pain such as interstitial cystitis and chronic prostatitis, or a disease accompanied by a pain, whose activity relies on its excellent trkA receptor-inhibiting activity. [MEANS FOR SOLVING PROBLEMS] Disclosed is a novel azolecarboxamide compound having a thiazole or oxazole ring bound to a benzene, pyridine, pyridazine, thiophene, pyrazole or pyrrole ring through a carboxamide or a salt of the azolecarboxamide compound. It is confirmed that the azolecarboxamide compound or the salt thereof has a potent trkA receptor-inhibiting activity. It is found that the azolecarboxamide compound or the salt thereof can be used as a highly effective and highly safe therapeutic or prophylactic agent for frequent urination, urinary urgency or urinary incontinence associated with a lower urinary tract disease including overactive bladder, a lower urinary tract disease accompanied by a lower urinary tract pain such as interstitial cystitis and chronic prostatitis, or a disease accompanied by a pain.
PCT/JP2008/069263 2007-10-24 2008-10-23 Azolecarboxamide compound or salt thereof WO2009054468A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SI200831299T SI2206707T1 (en) 2007-10-24 2008-10-23 Azolecarboxamide compound or salt thereof
JP2009538260A JP5321467B2 (en) 2007-10-24 2008-10-23 Azole carboxamide compound or salt thereof
ES08842145.8T ES2498065T3 (en) 2007-10-24 2008-10-23 Azolcarboxamide compound or salt thereof
KR1020107006536A KR101504787B1 (en) 2007-10-24 2008-10-23 Azolecarboxamide compound or salt thereof
CA2703106A CA2703106C (en) 2007-10-24 2008-10-23 Azolecarboxamide derivatives as trka inhibitors
CN2008801138204A CN101835764B (en) 2007-10-24 2008-10-23 Azolecarboxamide compound or salt thereof
BRPI0818201A BRPI0818201B8 (en) 2007-10-24 2008-10-23 azolecarboxamide compound or salt thereof and use thereof for the treatment of urinary frequency, urinary urgency, urinary incontinence and lower urinary tract pain associated with various lower urinary tract diseases, and various diseases accompanied by pain
DK08842145.8T DK2206707T3 (en) 2007-10-24 2008-10-23 AZOLCARBOXAMIDE COMPOUND OR SALT THEREOF
PL08842145T PL2206707T3 (en) 2007-10-24 2008-10-23 Azolecarboxamide compound or salt thereof
US12/739,433 US8304547B2 (en) 2007-10-24 2008-10-23 Azolecarboxamide compound or salt thereof
MX2010004499A MX2010004499A (en) 2007-10-24 2008-10-23 Azolecarboxamide compound or salt thereof.
EP08842145.8A EP2206707B1 (en) 2007-10-24 2008-10-23 Azolecarboxamide compound or salt thereof
AU2008314922A AU2008314922B2 (en) 2007-10-24 2008-10-23 Azolecarboxamide compound or salt thereof
IL205071A IL205071A (en) 2007-10-24 2010-04-14 Azolecarboxamide compound or salt thereof, a pharmaceutical composition comprising the same and uses thereof
ZA2010/02608A ZA201002608B (en) 2007-10-24 2010-04-14 Azolecarboxamide compound or salt thereof
HRP20140970AT HRP20140970T1 (en) 2007-10-24 2014-10-10 Azolecarboxamide compound or salt thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-276894 2007-10-24
JP2007276894 2007-10-24

Publications (1)

Publication Number Publication Date
WO2009054468A1 true WO2009054468A1 (en) 2009-04-30

Family

ID=40579570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069263 WO2009054468A1 (en) 2007-10-24 2008-10-23 Azolecarboxamide compound or salt thereof

Country Status (21)

Country Link
US (1) US8304547B2 (en)
EP (1) EP2206707B1 (en)
JP (1) JP5321467B2 (en)
KR (1) KR101504787B1 (en)
CN (1) CN101835764B (en)
AU (1) AU2008314922B2 (en)
BR (1) BRPI0818201B8 (en)
CA (1) CA2703106C (en)
CY (1) CY1115547T1 (en)
DK (1) DK2206707T3 (en)
ES (1) ES2498065T3 (en)
HR (1) HRP20140970T1 (en)
IL (1) IL205071A (en)
MX (1) MX2010004499A (en)
PL (1) PL2206707T3 (en)
PT (1) PT2206707E (en)
RU (1) RU2461551C2 (en)
SI (1) SI2206707T1 (en)
TW (1) TWI418557B (en)
WO (1) WO2009054468A1 (en)
ZA (1) ZA201002608B (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011043371A1 (en) * 2009-10-07 2011-04-14 アステラス製薬株式会社 Oxazole compound
EP2416795A1 (en) * 2009-04-09 2012-02-15 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2013022083A1 (en) 2011-08-11 2013-02-14 アステラス製薬株式会社 Novel anti-human ngf antibody
JP2014506599A (en) * 2011-02-25 2014-03-17 アイアールエム・リミテッド・ライアビリティ・カンパニー Pyrazolo [1,5-A] pyridine as a TRK inhibitor
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
JP2015504067A (en) * 2012-01-04 2015-02-05 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ N-aminosulfonylbenzamide
AU2009322346B2 (en) * 2008-12-03 2015-07-02 The Scripps Research Institute Stem cell cultures
WO2016162870A1 (en) 2015-04-07 2016-10-13 Ilana Nathan Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
US9499462B2 (en) 2011-02-02 2016-11-22 Cognition Therapeutics, Inc. Isolated compounds from turmeric oil and methods of use
JP2017508729A (en) * 2014-01-24 2017-03-30 アッヴィ・インコーポレイテッド Furo-3-carboxamide derivatives and methods of use
US9796672B2 (en) 2014-01-31 2017-10-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
US9815770B2 (en) 2009-07-31 2017-11-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US9902734B2 (en) 2010-03-19 2018-02-27 Indiana State University Nicotinic acetylcholine receptor agonists
US9982000B2 (en) * 2015-04-22 2018-05-29 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
CN108473450A (en) * 2016-01-01 2018-08-31 阿达玛阿甘股份有限公司 The preparation method of 1,1,3- trioxy- -1,2- benzothiazole -6- formamides
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2021191762A (en) * 2013-07-31 2021-12-16 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 2-benzoyl aminobenzamide derivative as bcl-3 inhibitor
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11370787B2 (en) 2019-08-30 2022-06-28 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771592A1 (en) * 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Substituted heterocyclic derivatives for the treatment of pain and epilepsy
US8435976B2 (en) * 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
PE20130405A1 (en) 2010-04-07 2013-04-10 Hoffmann La Roche PIRAZOL-4-IL-HETEROCICLIL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
US20130261130A1 (en) * 2010-11-01 2013-10-03 Shaheen Ahmed Neurotrypsin inhibitors
US20140113898A1 (en) * 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
MX2014003612A (en) 2011-09-27 2014-07-09 Hoffmann La Roche Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use.
JP6160613B2 (en) 2012-04-26 2017-07-12 小野薬品工業株式会社 Trk inhibitory compound
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
SG11201610201UA (en) 2014-06-06 2017-01-27 Astellas Pharma Inc 2-acylaminothiazole derivative or salt thereof
CA2959290A1 (en) * 2014-08-26 2016-03-03 Astellas Pharma Inc. 2-aminothiazole derivative or salt thereof
CN105601585B (en) * 2015-12-17 2018-01-05 浙江工业大学 A kind of carboxamides and its preparation and application containing thiazole ring
KR102614814B1 (en) 2017-05-15 2023-12-20 카그니션 테라퓨틱스, 인코퍼레이티드 Composition for treating neurodegenerative diseases
RU2768755C1 (en) 2018-05-09 2022-03-24 ЭлДжи КЕМ, ЛТД. Novel compound exhibiting enteropeptidase inhibiting activity
CN109627207A (en) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 A kind of preparation method of 3- (difluoro-methoxy) piperidine hydrochlorate
TW202315628A (en) * 2021-06-24 2023-04-16 南韓商Ｌｇ化學股份有限公司 Novel pyridine derivative compound as ron inhibitor
EP4159743A1 (en) * 2021-09-30 2023-04-05 ETH Zurich Methods for preparing pyridazine compounds
WO2024011155A1 (en) * 2022-07-07 2024-01-11 Libra Therapeutics, Inc. Oxazole trpml1 agonists and uses thereof

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016954A1 (en) * 1994-12-02 1996-06-06 Agrevo Uk Limited Derivatives of anthranilic acid useful as fungicides
WO2001014380A1 (en) 1999-08-20 2001-03-01 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
WO2001032653A1 (en) 1999-11-04 2001-05-10 Cephalon, Inc. Heterocyclic substituted pyrazolones
JP2001278872A (en) * 2000-03-27 2001-10-10 Banyu Pharmaceut Co Ltd New aminothiazole derivative
WO2001078698A2 (en) 2000-04-13 2001-10-25 Warner-Lambert Company Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
WO2002020513A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Oxindole derivatives
WO2003027111A1 (en) 2001-09-27 2003-04-03 Smithkline Beecham Corporation Chemical compounds
JP2003231687A (en) 2002-02-04 2003-08-19 Japan Tobacco Inc Pyrazolyl condensed ring compound and pharmaceutical use thereof
WO2004018428A1 (en) * 2002-08-23 2004-03-04 Pharmacia & Upjohn Company Llc Antibacterial benzoic acid derivatives
WO2005049033A1 (en) 2003-11-17 2005-06-02 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosyne kinases
WO2005076695A2 (en) 2004-02-11 2005-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
WO2005103010A2 (en) 2004-04-21 2005-11-03 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
WO2007014926A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
WO2007030939A2 (en) 2005-09-15 2007-03-22 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
WO2007035478A2 (en) * 2005-09-20 2007-03-29 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007061882A2 (en) 2005-11-18 2007-05-31 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2007104557A2 (en) * 2006-03-15 2007-09-20 4Sc Ag Novel heterocyclic nf-kb inhibitors
WO2007123269A1 (en) * 2006-04-19 2007-11-01 Astellas Pharma Inc. Azolecarboxamide derivative

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395932A (en) 1993-04-30 1995-03-07 G. D. Searle & Co. 2,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
JP2002512633A (en) 1997-06-26 2002-04-23 イーライ・リリー・アンド・カンパニー Antithrombotic agent
CN1325385A (en) 1998-11-09 2001-12-05 詹姆斯·布莱克基金有限公司 Gastrin and cholecystokinin receptor ligands
PL215901B1 (en) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
RU2247725C2 (en) 2000-11-16 2005-03-10 Санкио Компани, Лимитед 1-methylcarbapenam derivatives
AU2002248432A1 (en) 2001-02-14 2002-08-28 Sankyo Company, Limited Oxazole derivatives, their preparation and their use as cytokine inhibitors
JP2002338537A (en) 2001-05-16 2002-11-27 Mitsubishi Pharma Corp Amide compound and its medicinal use
AR034897A1 (en) 2001-08-07 2004-03-24 Hoffmann La Roche N-MONOACILATED DERIVATIVES OF O-PHENYLENDIAMINS, THEIR HETEROCICLICAL ANALOGS OF SIX MEMBERS AND THEIR USE AS PHARMACEUTICAL AGENTS
ATE479667T1 (en) 2003-02-06 2010-09-15 Bristol Myers Squibb Co THIAZOLYL-BASED COMPOUNDS SUITABLE AS KINASE INHIBITORS
CA2515215A1 (en) * 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
DE10306250A1 (en) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituted N-aryl heterocycles, processes for their preparation and their use as pharmaceuticals
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US7427683B2 (en) 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
JP2007525460A (en) 2003-04-25 2007-09-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド c-fms kinase inhibitor
US20050113566A1 (en) 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
FR2856685B1 (en) 2003-06-25 2005-09-23 Merck Sante Sas THIAZOLYLPIPERIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
PE20050444A1 (en) 2003-10-31 2005-08-09 Takeda Pharmaceutical PYRIDINE COMPOUNDS AS PEPTIDASE INHIBITORS
EP2140865A1 (en) 2003-11-14 2010-01-06 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
ES2401138T3 (en) 2004-08-13 2013-04-17 Genentech, Inc. Thiazole-based enzyme inhibitors that use ATP
DE102004039789A1 (en) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Aryl-substituted polycyclic amines, process for their preparation and their use as pharmaceuticals
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7601745B2 (en) * 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
WO2006044527A1 (en) * 2004-10-15 2006-04-27 Amgen Inc. Imidazole derivatives as vanilloid receptor ligands
DE602005023333D1 (en) * 2004-10-15 2010-10-14 Takeda Pharmaceutical KINASE INHIBITORS
ATE437864T1 (en) * 2004-10-22 2009-08-15 Janssen Pharmaceutica Nv AROMATIC AMIDES AS C-FMS KINASE INHIBITORS
WO2006116355A1 (en) 2005-04-22 2006-11-02 Kalypsys, Inc. Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
EA200702445A1 (en) 2005-05-09 2008-04-28 Ачиллион Фармасьютикалз, Инк. THIAZOLE COMPOUNDS AND METHODS OF THEIR APPLICATION
JP2008543965A (en) 2005-06-28 2008-12-04 タケダ・ケンブリッジ・リミテッド Heterocyclic non-peptide GNRH antagonist
US7700552B2 (en) 2005-07-29 2010-04-20 Medivir Ab Macrocyclic inhibitors of hepatitis C virus
AR055203A1 (en) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd BENZOTIOPHENE DERIVATIVES WITH ANTIPSYTICAL PROPERTIES
CN101263130B (en) 2005-09-13 2011-03-09 詹森药业有限公司 2-aniline-4-aryl substituted thiazole derivatives
KR101052122B1 (en) 2005-10-25 2011-07-26 시오노기세야쿠 가부시키가이샤 Aminodihydrothiazine derivatives
BRPI0619052A2 (en) 2005-11-28 2011-09-20 Hoffmann La Roche compounds, process for their preparation, pharmaceutical compositions comprising them, method for the therapeutic and / or prophylactic treatment of diseases that are modulated by diacylglycerol acyltransferase inhibitors, and their use
JP2009529059A (en) 2006-03-08 2009-08-13 アキリオン ファーマシューティカルズ，インコーポレーテッド Substituted aminothiazole derivatives having anti-hepatitis C virus activity
CA2659512C (en) 2006-06-06 2015-09-08 Critical Therapeutics, Inc. Novel piperazines, pharmaceutical compositions and methods of use thereof
GB0614070D0 (en) 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
EP1881001A1 (en) * 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
KR20090082440A (en) 2006-10-31 2009-07-30 쉐링 코포레이션 2-amin0thiaz0le-4-carb0xylic amides as protein kinase inhibitors
EP2078002B1 (en) 2006-10-31 2013-08-28 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
US9206142B2 (en) 2006-10-31 2015-12-08 Merck Sharp & Dohme Corp. Anilinopiperazine derivatives and methods of use thereof
WO2008059214A1 (en) 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016954A1 (en) * 1994-12-02 1996-06-06 Agrevo Uk Limited Derivatives of anthranilic acid useful as fungicides
WO2001014380A1 (en) 1999-08-20 2001-03-01 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
WO2001032653A1 (en) 1999-11-04 2001-05-10 Cephalon, Inc. Heterocyclic substituted pyrazolones
JP2001278872A (en) * 2000-03-27 2001-10-10 Banyu Pharmaceut Co Ltd New aminothiazole derivative
WO2001078698A2 (en) 2000-04-13 2001-10-25 Warner-Lambert Company Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
WO2002020479A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
WO2002020513A1 (en) 2000-09-01 2002-03-14 Glaxo Group Limited Oxindole derivatives
WO2003027111A1 (en) 2001-09-27 2003-04-03 Smithkline Beecham Corporation Chemical compounds
JP2003231687A (en) 2002-02-04 2003-08-19 Japan Tobacco Inc Pyrazolyl condensed ring compound and pharmaceutical use thereof
WO2004018428A1 (en) * 2002-08-23 2004-03-04 Pharmacia & Upjohn Company Llc Antibacterial benzoic acid derivatives
WO2005049033A1 (en) 2003-11-17 2005-06-02 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosyne kinases
WO2005076695A2 (en) 2004-02-11 2005-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
WO2005103010A2 (en) 2004-04-21 2005-11-03 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
WO2007014926A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
WO2007030939A2 (en) 2005-09-15 2007-03-22 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
WO2007030934A2 (en) 2005-09-15 2007-03-22 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
WO2007035478A2 (en) * 2005-09-20 2007-03-29 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007061882A2 (en) 2005-11-18 2007-05-31 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2007104557A2 (en) * 2006-03-15 2007-09-20 4Sc Ag Novel heterocyclic nf-kb inhibitors
WO2007123269A1 (en) * 2006-04-19 2007-11-01 Astellas Pharma Inc. Azolecarboxamide derivative

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
"Bunshi Sekkei", vol. 7, 1990, HIROKAWA PUBLISHING COMPANY, article "Iyakuhin no Kaihatsu", pages: 163 - 198
"Heterocyclic Compounds", vol. 45
"Heterocyclic Compounds", vol. 60
"Jikken Kagaku Koza", vol. 19, 1992, MARUZEN
"Jikken Kagaku Koza", vol. 20, 1992, MARUZEN
"Jikken Kagaku Koza", vol. 22, 1992, MARUZEN
"Jikken Kagaku Koza", vol. 23, 1992, MARUZEN
"Jikken Kagaku Koza", vol. 24, 1992, MARUZEN
"Jikken Kagaku Koza", vol. 25, 1992, MARUZEN
"Jikken Kagaku Koza", vol. 26, 1992, MARUZEN
"Protective Groups in Organic Synthesis"
BRITISH JOURNAL OF UROLOGY, vol. 79, 1997
CANCER RESEARCH, vol. 59, 1999, pages 2395 - 2401
COMPENDIUM OF ORGANIC SYNTHETIC METHODS, vol. 1-3
COMPREHENSIVE ORGANIC CHEMISTRY, vol. 4
GENERAL OUTLINE PRELIMINARILY DESCRIBED FOR THE 99TH AMERICAN UROLOGY ASSOCIATION, 2004
GREENE; WUTS: "Protective Groups in Organic Synthesis", 1999
HETEROCYCLIC COMPOUNDS, vol. 60
LI, J. ET AL.: "Preparation of novel antibacterial agents. Replacement of the central aromatic ring with heterocycles", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, no. 8, 2007, pages 2347 - 2350, XP022009263 *
NEUROSCIENCE, vol. 78, 1997, pages 449 - 459
PAIN, vol. 116, 2005, pages 8 - 16
PAIN, vol. 81, 1999, pages 245 - 55
PHILLIPS, A. J.; WIPF, P.; WILLIAMS, D. R. ET AL., ORG LETT, vol. 2, no. 8, 2000, pages 1165 - 1168
PROG. MED., vol. 5, 1985, pages 2157 - 2161
REVIEWS IN THE NEUROSCIENCES, vol. 8, 1997, pages 13 - 27
See also references of EP2206707A4
THE JOURNAL OF UROLOGY, vol. 173, 2005, pages 1016 - 1021

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10351822B2 (en) 2008-12-03 2019-07-16 The Scripps Research Institute Methods of enhancing cell survival of stem cells
US10975352B2 (en) 2008-12-03 2021-04-13 The Scripps Research Institute Methods of enhancing cell survival of stem cells
AU2009322346B2 (en) * 2008-12-03 2015-07-02 The Scripps Research Institute Stem cell cultures
US9340525B2 (en) 2008-12-03 2016-05-17 The Scripps Research Institute Stem cell cultures
US9896655B2 (en) 2008-12-03 2018-02-20 The Scripps Research Institute Methods of enhancing cell survival of stem cells
EP2416795A1 (en) * 2009-04-09 2012-02-15 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
JP2012523418A (en) * 2009-04-09 2012-10-04 コグニション セラピューティクス インク． Cognitive decline inhibitors
EP2416795A4 (en) * 2009-04-09 2013-12-25 Cognition Therapeutics Inc Inhibitors of cognitive decline
US9365491B2 (en) 2009-04-09 2016-06-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US9815770B2 (en) 2009-07-31 2017-11-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
WO2011043371A1 (en) * 2009-10-07 2011-04-14 アステラス製薬株式会社 Oxazole compound
US9902734B2 (en) 2010-03-19 2018-02-27 Indiana State University Nicotinic acetylcholine receptor agonists
US9499462B2 (en) 2011-02-02 2016-11-22 Cognition Therapeutics, Inc. Isolated compounds from turmeric oil and methods of use
JP2014506599A (en) * 2011-02-25 2014-03-17 アイアールエム・リミテッド・ライアビリティ・カンパニー Pyrazolo [1,5-A] pyridine as a TRK inhibitor
WO2013022083A1 (en) 2011-08-11 2013-02-14 アステラス製薬株式会社 Novel anti-human ngf antibody
JP2015504067A (en) * 2012-01-04 2015-02-05 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ N-aminosulfonylbenzamide
EP3181564A1 (en) 2012-11-20 2017-06-21 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
JP7241134B2 (en) 2013-07-31 2023-03-16 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 2-benzoylaminobenzamide derivatives as BCL-3 inhibitors
JP2021191762A (en) * 2013-07-31 2021-12-16 ユニバーシティ カレッジ カーディフ コンサルタンツ リミテッド 2-benzoyl aminobenzamide derivative as bcl-3 inhibitor
JP2017508729A (en) * 2014-01-24 2017-03-30 アッヴィ・インコーポレイテッド Furo-3-carboxamide derivatives and methods of use
US9796672B2 (en) 2014-01-31 2017-10-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
US10207991B2 (en) 2014-01-31 2019-02-19 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
JP2020183405A (en) * 2015-04-07 2020-11-12 イーエルエイ ファーマ リミテッドＥｌａ Ｐｈａｒｍａ Ｌｔｄ Compositions for treating and/or preventing cell and/or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or enzymes structurally related to them
WO2016162870A1 (en) 2015-04-07 2016-10-13 Ilana Nathan Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
US10208074B2 (en) 2015-04-22 2019-02-19 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
US9982000B2 (en) * 2015-04-22 2018-05-29 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
US11370808B2 (en) 2015-04-22 2022-06-28 Rigel Pharmaceuticals, Inc. Pyrazole compounds and methods for making and using the compounds
AU2016252869B2 (en) * 2015-04-22 2020-10-22 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
US10208075B2 (en) 2015-04-22 2019-02-19 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
CN108473450B (en) * 2016-01-01 2022-05-10 阿达玛阿甘股份有限公司 Process for preparing 1,1, 3-trioxo-1, 2-benzothiazole-6-carboxamides
CN108473450A (en) * 2016-01-01 2018-08-31 阿达玛阿甘股份有限公司 The preparation method of 1,1,3- trioxy- -1,2- benzothiazole -6- formamides
US11932613B2 (en) 2016-01-01 2024-03-19 Adama Agan Ltd. Process for preparing 1,1,3-trioxo-1,2-benzothiazole-6-carboxamide
US10710986B2 (en) 2018-02-13 2020-07-14 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11555029B2 (en) 2018-02-13 2023-01-17 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10774071B2 (en) 2018-07-13 2020-09-15 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11370787B2 (en) 2019-08-30 2022-06-28 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11851429B2 (en) 2020-05-19 2023-12-26 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators

Also Published As

Publication number Publication date
DK2206707T3 (en) 2014-08-11
ZA201002608B (en) 2011-07-27
PL2206707T3 (en) 2015-01-30
ES2498065T3 (en) 2014-09-24
EP2206707B1 (en) 2014-07-23
HRP20140970T1 (en) 2015-01-30
PT2206707E (en) 2014-09-25
CA2703106A1 (en) 2009-04-30
CA2703106C (en) 2015-12-01
CN101835764A (en) 2010-09-15
MX2010004499A (en) 2010-05-20
AU2008314922B2 (en) 2013-08-29
BRPI0818201B1 (en) 2019-01-29
IL205071A (en) 2015-08-31
EP2206707A4 (en) 2011-08-17
KR101504787B1 (en) 2015-03-20
US20100249088A1 (en) 2010-09-30
RU2010120676A (en) 2011-11-27
AU2008314922A1 (en) 2009-04-30
TW200932743A (en) 2009-08-01
IL205071A0 (en) 2010-11-30
CN101835764B (en) 2012-09-19
TWI418557B (en) 2013-12-11
CY1115547T1 (en) 2017-01-04
JPWO2009054468A1 (en) 2011-03-10
BRPI0818201A2 (en) 2015-04-22
KR20100071047A (en) 2010-06-28
JP5321467B2 (en) 2013-10-23
RU2461551C2 (en) 2012-09-20
US8304547B2 (en) 2012-11-06
BRPI0818201B8 (en) 2021-05-25
SI2206707T1 (en) 2014-11-28
EP2206707A1 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
WO2009054468A1 (en) Azolecarboxamide compound or salt thereof
WO2009111083A3 (en) In vivo temporal control of activ at able matrix- degrading enzymes
IL260508B (en) Anti-ngf antagonist antibody for treatment or prevention of urinary urgency associated with interstitial cystitis and/or painful bladder syndrome and/or bladder pain syndrome
WO2009020802A3 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
WO2008057856A3 (en) Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
WO2007143098A8 (en) Hepatocyte growth factor (hgf) binding proteins
NZ602734A (en) Therapeutic dll4 binding proteins
WO2008036678A3 (en) Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
WO2006023629A3 (en) Treatment of pediatric multiple sclerosis
EP2025058A4 (en) Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
MX2010004503A (en) Oxadiazolidinedione compound.
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2009032321A3 (en) A method for treating diabetes
WO2006131951A3 (en) MOLECULES THAT ARE ABLE TO INHIBIT THE BINDING BETWEEN NGF AND THE TrkA RECEPTOR AS ANALGESICS WITH PROLONGED EFFECT
WO2007025613A3 (en) Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
IL183557A0 (en) The use of the non-opiate analgesic drug flupirtine for the treatment of overactive bladder and associated diseases including urge incontinence, urinary flow problems as a result of prostate hyperplasia and irritable bowl syndrome
WO2010122980A8 (en) NOVEL THYROID HORMONE β RECEPTOR AGONIST
WO2011061519A3 (en) Topical foam composition
NZ600874A (en) Fluorinated derivatives of deferiprone
WO2009045543A8 (en) Treatment of conditions related to shock
FR2984148B1 (en) OXIDATION COLORING PROCESS USING A RICH BODY COMPOSITION AND METAL CATALYSTS, AND APPROPRIATE DEVICE
WO2009068659A3 (en) Novel disease treatment by predicting drug association
WO2005118538A3 (en) Arylsulfonamides and uses as hydroxysteroid dehydrogenase
WO2007109459A3 (en) Pyridines and pyridine n-oxides as modulators of thrombin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880113820.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08842145

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009538260

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107006536

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12010500788

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2008314922

Country of ref document: AU

Ref document number: 205071

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2008842145

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2703106

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12739433

Country of ref document: US

Ref document number: MX/A/2010/004499

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008314922

Country of ref document: AU

Date of ref document: 20081023

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010120676

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0818201

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100427